- Home
- ZENV vs TCRX Comparison
ZENV vs TCRX Comparison
Compare ZENV & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- TCRX
- Stock Information
- Founded
- ZENV 2005
- TCRX 2018
- Country
- ZENV Brazil
- TCRX United States
- Employees
- ZENV N/A
- TCRX N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- TCRX Health Care
- Exchange
- ZENV Nasdaq
- TCRX Nasdaq
- Market Cap
- ZENV 80.2M
- TCRX 67.9M
- IPO Year
- ZENV 2021
- TCRX 2021
- Fundamental
- Price
- ZENV $1.52
- TCRX $1.60
- Analyst Decision
- ZENV
- TCRX Strong Buy
- Analyst Count
- ZENV 0
- TCRX 6
- Target Price
- ZENV N/A
- TCRX $9.83
- AVG Volume (30 Days)
- ZENV 60.0K
- TCRX 549.2K
- Earning Date
- ZENV 05-06-2025
- TCRX 05-12-2025
- Dividend Yield
- ZENV N/A
- TCRX N/A
- EPS Growth
- ZENV N/A
- TCRX N/A
- EPS
- ZENV N/A
- TCRX N/A
- Revenue
- ZENV $173,594,726.00
- TCRX $2,816,000.00
- Revenue This Year
- ZENV $28.66
- TCRX $47.30
- Revenue Next Year
- ZENV $2.98
- TCRX $74.30
- P/E Ratio
- ZENV N/A
- TCRX N/A
- Revenue Growth
- ZENV 23.49
- TCRX N/A
- 52 Week Low
- ZENV $1.02
- TCRX $1.02
- 52 Week High
- ZENV $3.88
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- ZENV 50.89
- TCRX 55.27
- Support Level
- ZENV $1.26
- TCRX $1.02
- Resistance Level
- ZENV $1.51
- TCRX $1.73
- Average True Range (ATR)
- ZENV 0.10
- TCRX 0.17
- MACD
- ZENV 0.02
- TCRX 0.08
- Stochastic Oscillator
- ZENV 100.00
- TCRX 81.69
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.